Independent Clinical Study Confirms Initial Findings on Over-the-Counter Cold Remedy

February 08, 2000

New York (MedscapeWire) Feb 8 — Gel Tech LLC, a joint venture between Gum Tech International Inc and BioDelivery Technologies Inc announced the results of the first independent scientific study on Zicam, an over-the-counter homeopathic cold remedy. Results from the clinical research, conducted by lead investigator Dr. Michael Hirt, a graduate of Harvard Medical School and a clinical faculty member at the University of California at Los Angeles, confirm the previously announced findings of the company's initial internal study. According to the independent study, Zicam, a proprietary nasal gel, reduced the duration of the common cold by an average of 78% when taken at the onset.

"Gel Tech had conducted an internal study which demonstrated a substantial improvement in patients using Zicam. As an independent researcher, I wanted to see if the results could be duplicated. We conducted a double blind placebo controlled independent study, much like the government requires of drug companies when they are testing drugs," said Dr. Hirt. "Those patients taking Zicam resolved their symptoms an average of 78% faster than those patients receiving the placebo. There was quite a substantial difference in terms of how quickly people felt better about their symptoms."

Zicam was specifically designed to significantly reduce the duration and severity of the common cold, including nasal congestion, sneezing, coughing, and sore throat. Colds are generally caused when viruses bind with the ICAM-1 receptor sites on cells lining the nasal cavity. Scientists hypothesize that ionic zinc may fill grooves or canyons on the cold-causing viruses, inhibiting or blocking the virus's ability to bind to the receptor sites and interrupting the infection cycle. Zicam uses a proprietary gel matrix to apply an emulsification of ionic zinc directly to the nasal cavity.

"The study is being written up and will be submitted for publication. The study was conducted according to the highest standards and represents good, quality research, which I hope will be recognized by publication," concluded Dr. Hirt.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.